Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported revenue of 25.31 billion yuan for 2025, a year-on-year increase of 5.9%, and a net profit attributable to shareholders of 5.11 billion yuan, a year-on-year increase of 65.3% [8] - The Q4 revenue exceeded previous expectations, with a revenue of 6.53 billion yuan, a year-on-year increase of 8.3%, and a net profit of 1.17 billion yuan, a year-on-year increase of 229.8% [8] - The company expects a revenue growth rate of 2% to 6% for 2026, with a net opening of approximately 1,600 hotels [8] Financial Projections - Total revenue projections for 2024A to 2028E are as follows: 23.89 billion yuan (2024A), 25.31 billion yuan (2025A), 27.05 billion yuan (2026E), 28.91 billion yuan (2027E), and 30.86 billion yuan (2028E) [1] - Net profit projections for the same period are: 3.09 billion yuan (2024A), 5.11 billion yuan (2025A), 5.84 billion yuan (2026E), 6.53 billion yuan (2027E), and 7.18 billion yuan (2028E) [1] - The company anticipates a RevPAR (Revenue per Available Room) growth in 2026, with a low single-digit increase expected [8]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Insights - The company's revenue is recovering, with a projected total revenue of 3.26 billion yuan for 2025, representing a year-on-year growth of 7.32%. However, the net profit attributable to shareholders is expected to decline by 13.68% to 746.8 million yuan [7] - The company is focusing on resource integration and the progress of new projects, which are expected to contribute to incremental revenue in the future [7] - The company has a unique position as the only publicly listed cultural tourism platform in the Xinjiang Autonomous Region, with potential for resource integration under the control of the Xinjiang State-owned Assets Supervision and Administration Commission [7] Financial Summary - Total revenue projections for 2024A to 2028E are as follows: 3.0371 billion yuan (2024A), 3.2595 billion yuan (2025A), 3.5567 billion yuan (2026E), 3.8489 billion yuan (2027E), and 4.1353 billion yuan (2028E) [1] - The net profit attributable to shareholders is projected to be 865.1 million yuan (2024A), 746.8 million yuan (2025A), 891.1 million yuan (2026E), 1.0287 billion yuan (2027E), and 1.1526 billion yuan (2028E) [1] - The earnings per share (EPS) are expected to be 0.56 yuan (2024A), 0.48 yuan (2025A), 0.57 yuan (2026E), 0.66 yuan (2027E), and 0.74 yuan (2028E) [1] - The price-to-earnings (P/E) ratio is projected to be 61.69 (2024A), 71.46 (2025A), 59.89 (2026E), 51.88 (2027E), and 46.30 (2028E) [1]

Investment Rating - The report maintains an "Overweight" rating for the non-bank financial sector [1] Core Insights - The non-bank financial sector is expected to stabilize as medium to long-term capital continues to enter the market [1] - The insurance industry shows rapid growth in total assets and a significant increase in equity allocation [2] - The report highlights the cyclical nature of the insurance industry, predicting improvements in both liabilities and investments as the economy recovers [2] Summary by Sections Non-Bank Financial Sector Performance - In the recent five trading days (March 16-20, 2026), the multi-financial and insurance sectors outperformed the CSI 300 index, with multi-financial down 1.31% and insurance down 1.95% [11] - Year-to-date, the multi-financial sector has performed the best, with a decline of 2.25%, while the insurance sector has seen a decline of 10.78% [12] Securities - Trading volume has increased, with the average daily stock trading amount reaching 28,410 billion yuan in March 2026, up 66.15% year-on-year [16] - The report notes a significant increase in margin trading balances, which reached 26,501 billion yuan, a 35.91% year-on-year increase [16] - The average price-to-book (PB) ratio for the securities industry is projected at 1.1x for 2026E, indicating potential for growth [27] Insurance - The total assets of insurance companies and asset management firms reached 41.3 trillion yuan by the end of 2025, a 15.1% increase from the beginning of the year [29] - The insurance premium income for 2025 was 6.1 trillion yuan, reflecting a 7.4% year-on-year growth [29] - The average solvency ratio for insurance companies was 181% at the end of 2025, indicating strong financial health [29] Multi-Financial - The trust industry saw its asset scale reach 32.43 trillion yuan by mid-2025, a 20.11% year-on-year increase [38] - The futures market recorded a trading volume of 5.03 billion contracts in February 2026, with a transaction value of 55.59 trillion yuan, showing a 7.82% year-on-year growth [43] - The report suggests that the trust industry is entering a stable transition period, while the futures market is expected to see increased activity due to rising commodity price volatility [42][43] Recommendations - The report recommends focusing on the insurance sector, followed by securities and other multi-financial services, highlighting companies such as China Ping An, China Life, and CITIC Securities as key investment opportunities [6]

Investment Rating - The report maintains an "Overweight" rating for the non-bank financial sector [1] Core Insights - The non-bank financial sector is expected to stabilize as medium to long-term capital continues to enter the market, with a focus on the insurance and securities sub-sectors showing promising growth [2][5] Summary by Sections Insurance - The insurance industry has seen rapid growth in total assets, with a significant increase in equity allocation. As of the end of 2025, total assets of insurance companies and asset management firms reached 41.3 trillion yuan, a 15.1% increase from the beginning of the year. The original insurance premium income for 2025 was 6.1 trillion yuan, up 7.4% year-on-year [2][29] - The average comprehensive solvency adequacy ratio for insurance companies was 181% at the end of 2025, indicating strong financial health. The report highlights the cyclical nature of the insurance business, suggesting that as the economy recovers, both liabilities and investments will improve significantly [2][37] Securities - The securities sector has experienced a rise in trading volume, with the average daily trading amount for March 2026 reaching 28,410 billion yuan, a 66.15% increase year-on-year. The margin trading balance also increased by 35.91% year-on-year to 26,501 billion yuan [5][16] - The report emphasizes the potential for growth in brokerage, investment banking, and capital intermediary services due to favorable market conditions and policy support. The average price-to-book (PB) ratio for the securities industry is projected at 1.1x for 2026E, indicating a favorable valuation environment [5][27] Multi-Financial - The trust industry reported a total asset scale of 32.43 trillion yuan as of mid-2025, reflecting a 20.11% year-on-year growth. However, the profit growth has been modest, indicating a transitional phase for the industry [6][38] - The futures market saw a trading volume of 5.03 billion contracts in February 2026, with a transaction value of 55.59 trillion yuan, showing a 7.82% year-on-year increase. The report suggests that the expansion of trading varieties and increased demand for hedging will support future growth in this sector [6][43]

Group 1 - The report analyzes the causes of stagflation in the 1970s, attributing it to three main factors: Keynesian monetary and fiscal policies, geopolitical conflicts affecting oil supply, and the collapse of the Bretton Woods system leading to dollar depreciation [2][15][21] - The report highlights that during the stagflation periods, major asset classes exhibited distinct performances, with U.S. equities experiencing significant declines in the first stagflation phase (1973-1974) and recovering in the second phase (1979-1980) [3][22][30] - The bond market saw a substantial rise in interest rates, entering a bear market, particularly during the second stagflation phase when the 10-year Treasury yield exceeded 15% due to aggressive monetary tightening [26][30] Group 2 - The report suggests that the current macroeconomic environment in the U.S. shows signs of potential stagflation, with high fiscal deficits and inflationary pressures, while China's economy is positioned for recovery and high-quality development [1][14][31] - Insights from the historical performance of Japanese and U.S. equities during stagflation are relevant for the current A-share market, indicating that A-shares may not directly correlate with U.S. stagflation risks and could showcase relative advantages [4][34][36] - The report emphasizes that the energy sector is likely to perform well in a stagflation environment, as seen in historical trends where energy companies significantly increased profits during oil crises [44] Group 3 - The technology sector may face overall adjustments, but strong industry trends are expected to persist, with a focus on companies with competitive advantages and pricing power in storage, advanced processes, and semiconductor materials [5][52][53] - Consumer sectors historically underperformed during stagflation, but the report suggests that A-share consumer performance may not be overly pessimistic due to stronger domestic fundamentals and energy advantages [54] - High-end manufacturing sectors are expected to maintain relative resilience, benefiting from structural advantages in the current economic landscape [5][43]

Investment Rating - The investment rating for the company is "Accumulate" [1] Core Views - The company's revenue is recovering, with a projected total revenue of 3.26 billion yuan in 2025, representing a year-on-year growth of 7.32% [7] - The net profit attributable to shareholders is expected to be 746.8 million yuan in 2025, reflecting a year-on-year decrease of 13.68% [7] - The company is focusing on resource integration and the progress of new projects to drive future growth [7] Financial Summary - Total revenue projections for the company are as follows: 3.04 billion yuan in 2024, 3.26 billion yuan in 2025, 3.56 billion yuan in 2026, 3.85 billion yuan in 2027, and 4.14 billion yuan in 2028 [1] - The net profit attributable to shareholders is forecasted to be 865.1 million yuan in 2024, 746.8 million yuan in 2025, 891.1 million yuan in 2026, 1.03 billion yuan in 2027, and 1.15 billion yuan in 2028 [1] - The earnings per share (EPS) are projected to be 0.56 yuan in 2024, 0.48 yuan in 2025, 0.57 yuan in 2026, 0.66 yuan in 2027, and 0.74 yuan in 2028 [1] Business Performance - The company reported a stable growth in passenger transport and cableway operations, with revenues of 1.98 billion yuan and 470 million yuan respectively in 2025 [7] - The immersive performance segment has emerged as a new growth point, with a revenue increase of 100% year-on-year [7] - The company aims to optimize project offerings and strengthen operations at key scenic spots while expanding new projects [7]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The innovative drug sector is experiencing significant funding support, with a total of approximately 700 billion RMB raised in the A-share and Hong Kong markets from January 1, 2024, to March 21, 2026, to support R&D investments [15] - The BD (Business Development) income has become a crucial funding source for innovative drug research, with total contracts reaching 57.1 billion USD as of March 21, 2026, indicating a strong trend in the Chinese innovative drug market [18] - The report highlights a positive outlook for the innovative drug sector, particularly in small nucleic acid therapies, and suggests a ranking of preferred sub-sectors: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [8][11] Summary by Sections Industry Performance - The A-share pharmaceutical index has seen a decline of 2.77% this week and 2.90% year-to-date, underperforming the CSI 300 by 0.59% and 1.54% respectively [8] - The Hong Kong biotechnology index has increased by 0.48% this week and decreased by 0.97% year-to-date, outperforming the Hang Seng Technology Index by 2.60% and 10.63% respectively [8] Funding and Investment - From January 1, 2024, to March 21, 2026, the A-share pharmaceutical sector raised 11.8 billion RMB through equity financing and 2.5 billion RMB through convertible bonds [15] - The report emphasizes that the current funding situation in the pharmaceutical sector is robust, with most companies maintaining over one year of R&D funding coverage [18] R&D Progress and Company Developments - Several companies have made significant advancements in their R&D pipelines, including KX-826 for hair loss treatment and ABSK061 for achondroplasia, which received orphan drug designation from the FDA [8] - The report suggests specific companies to watch based on various therapeutic areas, including innovative drugs, ADCs, and small nucleic acids [11] Market Insights - The report notes that the overall market for pharmaceuticals is currently undervalued, with the pharmaceutical index trading at a P/E ratio of 35.19, which is 3.22 times lower than its historical average [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a revenue of 14.26 billion yuan for 2025, representing a year-on-year growth of 20.83%. The net profit was 1.06 billion yuan, down 18.37% year-on-year, but the adjusted net profit was 1.53 billion yuan, up 1.3% year-on-year [7] - The HNB (Heat Not Burn) business is expected to ramp up, with significant growth in the electronic atomization segment. The company is also expanding into new business areas such as medical and beauty atomization, which are anticipated to provide long-term growth opportunities [7] - The company is positioned as a global leader in atomization technology, with a multi-business matrix that is steadily advancing despite tightening regulatory policies [7] Financial Summary - Total revenue projections for the company are as follows: - 2024: 11.80 billion yuan - 2025: 14.26 billion yuan - 2026: 16.62 billion yuan - 2027: 19.77 billion yuan - 2028: 23.34 billion yuan - The projected net profit for the years 2026 to 2028 is as follows: - 2026: 1.26 billion yuan - 2027: 1.88 billion yuan - 2028: 2.79 billion yuan - The earnings per share (EPS) is projected to be: - 2024: 0.21 yuan - 2025: 0.17 yuan - 2026: 0.20 yuan - 2027: 0.30 yuan - 2028: 0.45 yuan [1][8]

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology industry [1] Core Insights - The innovative drug sector is experiencing significant funding support, with a total of approximately 700 billion RMB raised in the A-share and Hong Kong markets from January 1, 2024, to March 21, 2026, to support R&D investments [15] - The BD (Business Development) income has become a crucial funding source for innovative drug research, with total contracts reaching 57.1 billion USD as of March 21, 2026, indicating a strong trend in the Chinese innovative drug market [18] - The report highlights a positive outlook for the innovative drug sector, particularly in small nucleic acid therapies, and suggests a ranking of preferred sub-sectors: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [8] Summary by Sections Industry Performance - The A-share pharmaceutical index has seen a decline of 2.77% this week and 2.90% year-to-date, underperforming the CSI 300 by 0.59% and 1.54% respectively [8] - The Hong Kong biotechnology index has increased by 0.48% this week and decreased by 0.97% year-to-date, outperforming the Hang Seng Technology Index by 2.60% and 10.63% respectively [8] Funding and Investment - From January 1, 2024, to March 21, 2026, the A-share pharmaceutical sector raised 11.8 billion RMB through equity financing and 2.5 billion RMB through convertible bonds [15] - The Hong Kong pharmaceutical sector raised a total of 63.2 billion HKD during the same period [15] R&D Progress and Company Developments - Several companies have made significant advancements in their R&D, including KX-826 for hair loss treatment and ABSK061 for achondroplasia, which received orphan drug designation from the FDA [8] - The report emphasizes the importance of maintaining a robust financial foundation for ongoing clinical trials and pipeline expansion, with most companies having over one year of R&D funding coverage [18] Stock Recommendations - The report suggests focusing on specific companies based on various therapeutic areas, including innovative drugs, ADCs, small nucleic acids, and traditional Chinese medicine [11]

Investment Rating - The report maintains an "Overweight" rating for the real estate industry, indicating a positive outlook for the sector in the next six months [1]. Core Insights - Development investment decline has narrowed, with new construction and completion continuing to adjust. In January-February 2026, cumulative real estate development investment reached 961.2 billion yuan, a year-on-year change of -11.1%, with the decline narrowing by 6.1 percentage points compared to the entire year of 2025 [8]. - Sales show marginal improvement, with a reduction in the month-on-month decline of housing prices. In January-February 2026, the national commodity housing sales area was 92.93 million square meters, a year-on-year change of -13.5%, with the decline narrowing by 2.1 percentage points compared to December 2025 [19]. - Funding pressure remains, but the decline in self-raised funds has narrowed. In January-February 2026, the cumulative amount of funds in place for real estate development enterprises was 1.3 trillion yuan, a year-on-year change of -16.5%, with the decline expanding by 3.1 percentage points compared to the entire year of 2025 [31]. Summary by Sections 1. Development Investment and Construction - Development investment decline has narrowed, with a cumulative year-on-year change of -11.1% for January-February 2026 [8]. - New construction area continues to adjust, with a cumulative year-on-year change of -23.1% for January-February 2026 [9]. - Completion area continues to adjust, with a cumulative year-on-year change of -27.9% for January-February 2026 [16]. 2. Sales and Housing Prices - Sales decline has narrowed, with a cumulative year-on-year change of -13.5% in sales area for January-February 2026 [19]. - Housing price decline has slowed, with a month-on-month change of -0.3% in February 2026 for new homes [23]. 3. Funding Situation - Funding pressure remains, with a cumulative year-on-year change of -16.5% in funds in place for January-February 2026 [31]. - The decline in self-raised funds has narrowed, with a year-on-year change of -5.9% [38]. 4. Investment Recommendations - The report recommends several companies for investment: for real estate development, it suggests China Resources Land, New Town Holdings, and China Merchants Shekou, while also advising to pay attention to Poly Developments [43].